Prevention of Diabetic Kidney Disease: Negative Clinical Trials With Renin-Angiotensin System Inhibitors

American Journal of Kidney Diseases

Volumn 55, Issue 3, 2010, Pages 426-430

  Nelson, Robert G ^a   Tuttle, Katherine R ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; ENALAPRIL; HEMOGLOBIN A1C; LOSARTAN; PLACEBO;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; EDITORIAL; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 77049094652     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.10.001     Document Type: Editorial

References (23)

1. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49 2 suppl 2 (2007) S12-S154
2. Bilous R., Chaturvedi N., Sjølie A.K., et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151 1 (2009) 11-20
3. Mauer M., Zinman B., Gardiner R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361 1 (2009) 40-51
4. Ruggenenti P., Fassi A., Ilieva A.P., et al., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 19 (2004) 1941-1951
5. Patel A., and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 9590 (2007) 829-840
6. Yusuf S., Sleight P., Pogue J., et al., Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 3 (2000) 145-153
7. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349 9068 (1997) 1787-1792
8. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 14 (1993) 977-986
9. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 6 (2000) 381-389
10. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (1998) 837-853
11. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 9131 (1998) 854-865
12. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 2 (1995) 103-117
13. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A.W. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 15 (2008) 1577-1589
14. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 24 (2008) 2545-2559
15. Action in Diabetes and Cardiovascular Disease. Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 24 (2008) 2560-2572
16. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 2 (2009) 129-139
17. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
18. US Renal Data System. USRDS 2009 Annual Data Report; vol 2 (2009), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
19. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R., and UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 1 (2003) 225-232
20. US Renal Data System. USRDS 2009 Annual Data Report; vol 1 (2009), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
21. Chobanian A.V., Bakris G.L., Black H.R., et al., National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 6 (2003) 1206-1252
22. American Diabetes Association. Clinical practice recommendations 2009. Diabetes Care 32 suppl 1 (2009) S1-S98
23. National Kidney Foundation. KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43 5 suppl 1 (2004) S1-S290